ESC: Mavacamten Cuts Need for Septal Reduction Tx with Hypertrophic Cardiomyopathy
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Aug. 29, 2023 -- In patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), mavacamten reduces the need for septal reduction therapy (SRT) at week 56, according to a study published online Aug. 28 in JAMA Cardiology to coincide with the European Society of Cardiology Congress 2023, held from Aug. 25 to 28 in Amsterdam.
Milind Y. Desai, M.D., from the Cleveland Clinic, and colleagues examined the cumulative longer-term effect of mavacamten on the need for SRT through week 56 in a double-blind, placebo-controlled, randomized clinical trial. The analysis included 112 patients with symptomatic HCM who were either randomly assigned to mavacamten at baseline for 56 weeks or assigned to placebo with crossover to mavacamten from week 16 to week 56 (40-week exposure).
The researchers found that at week 56, five of 56 patients in the original mavacamten group and 10 of 52 patients in the placebo crossover group met composite SRT criteria, and 96 of 108 patients continued taking mavacamten long term. After 56 weeks, there was a sustained reduction in resting (mean difference, −34.0 mmHg and −33.2 mmHg in mavacamten and placebo-to-mavacamten groups, respectively) and Valsalva (mean difference, −45.6 mmHg and −54.6 mmHg) left ventricular outflow tract gradients. There was also an improvement in New York Heart Association class 1 or higher in 51 of 55 patients in the original mavacamten group and in 37 of 51 patients in the crossover group. A left ventricular ejection fraction <50 percent was seen in 11.1 percent of patients overall, representing 12.5 percent in the original mavacamten group and 9.6 percent in the placebo crossover group.
“Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring,” the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Long COVID Definitions, Care Models Are Evolving
MONDAY, May 20, 2024 -- Definitions of long COVID and care models are evolving, but considerable variability is seen in these models, according to a review published online May 21...
Recommendations Developed for People With HIV Wanting to Breastfeed
MONDAY, May 20, 2024 -- In an American Academy of Pediatrics clinical report published online May 20 in Pediatrics, recommendations are presented for breastfeeding among people...
Social Determinants of Health Impact Poststroke Mortality Risk
MONDAY, May 20, 2024 -- Social determinants of health have a cumulative impact on poststroke mortality, according to a study presented at the the annual European Stroke...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.